Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gaucher disease
Biotech
Sanofi GCS inhibitor fails ph. 3 Fabry trial but wins in Gaucher
Sanofi’s pipeline features various once-hyped candidates struggling to deliver in the clinic, and the latest data from venglustat continue this trend.
James Waldron
Feb 2, 2026 5:46am
Syncona merges Freeline, SwanBio into new gene therapy biotech
Jun 17, 2024 11:01am
Avrobio hopes to get investors back on gene therapy bandwagon
Dec 7, 2022 7:30am
Lilly doubles down on Prevail buy with $700M research hub
Feb 22, 2022 9:34am
Avrobio ditches Fabry, eyes 2023 trials for other gene therapies
Jan 4, 2022 10:08am
Vanqua nabs $85M from Lilly, OrbiMed, others for Gaucher, PD, AD
Sep 14, 2021 7:00am
